Project Grant R01HL181971
- This federal Project Grant award of $174,528, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify novel treatment targets for atrial myopathy, a condition that contributes to atrial fibrillation and associated heart failure, stroke, and mortality. The primary objective is to leverage human cohort data to discover circulating proteins and metabolites linked to both left atrial function and atrial myopathy, using...
- This $125,703 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the role of the SYNE1-giant gene in atrial cardiomyopathy. The principal investigator is conducting a comprehensive study to understand the mechanisms by which mutations in the SYNE1 gene, which encodes mechanosensitive proteins in the nuclear envelope, contribute to the development of atrial fibrillation and sinus node dysfunction....
- The University of Washington received a $663,578 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 15, 2025 through May 31, 2029, supports research to better diagnose and understand cardiac sarcoidosis, a form of inflammatory cardiomyopathy. The project aims to "perform 'deep phenotyping' with genetic testing, PET imaging, metabolomic studies, and voltage-guided endomyocardial...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,372,795 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The grant, effective January 15, 2025 through December 31, 2027, will provide infrastructure support to maintain the Cardiovascular Health Study (CHS) coordinating center, databases, and activities, including support for 78 ancillary studies. It will also assist investigators in developing new ancillary studies,...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- This Project Grant award of $231,000.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), to study the functional impact of atrial myosin mutations associated with familial atrial arrhythmia. The research aims to comprehensively analyze the effects of known genetic mutations in the a-cardiac myosin heavy chain, essential light chain, and regulatory light chain on myosin activity and sarcomere...
- This federal Project Grant award for $769,761 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the mechanisms by which obesity leads to atrial fibrillation. The awardee, Weill Medical College of Cornell University, is developing a mouse model of obesity-induced atrial fibrillation to investigate how nicotinamide adenine dinucleotide (NAD+) pathways and the ATF6 endoplasmic reticulum stress pathway...
- The National Institutes of Health's National Heart, Lung, and Blood Institute awarded a $464,502 project grant to Tarleton State University under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will fund the development of an interactive computer model of the left atrium's electrophysiology to study the underlying mechanisms leading to atrial fibrillation. Key objectives include: 1) constructing an anatomically accurate 3D model of the left...
- This Project Grant award, valued at $242,250.00 and awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to examine the relationship between atrial fibrillation, anticoagulation therapy, and retinal stroke. The research will utilize an instrumental variable approach to provide indirect evidence of the association between atrial fibrillation and retinal stroke, and how anticoagulation therapy may modify this relationship. The...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $733,999 to the University of South Florida to investigate the relationship between atrial microvascular/endothelial dysfunction and the development of postoperative atrial fibrillation (POAF). The key objectives are to: 1) Evaluate microvascular signaling pathways responsible for myogenic/vasomotor/endothelial dysfunction of the atrial microvasculature in POAF...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds a study to investigate the molecular mechanisms linking atrial cardiopathy to cardiovascular disease outcomes. The $1,657,473 award, granted on September 24, 2025, supports the use of proteomic and genomic methods in two diverse populations - individuals free of clinically recognized cardiovascular disease and patients with recent cryptogenic stroke - to identify novel protein biomarkers associated with atrial cardiopathy and related cardiovascular events. The primary outcomes of this research include atrial fibrillation, ischemic stroke, and other major adverse cardiovascular events. The University of Washington is the lead awardee on this grant, drawing on its extensive capabilities in executing complex, multidisciplinary biomedical research for federal agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 9/24/25 |